Pregled bibliografske jedinice broj: 713449
CURRENT TRENDS IN ACTIVITY AND SELECTIVITY PROFILING OF THERAPEUTIC MOLECULES
CURRENT TRENDS IN ACTIVITY AND SELECTIVITY PROFILING OF THERAPEUTIC MOLECULES // International Scientific and Professional Conference 15th Ružička days “TODAY SCIENCE – TOMMOROW INDUSTRY” - Book of abstracts / Drago Šubarić (ur.).
Osijek, 2014. (plenarno, međunarodna recenzija, sažetak, ostalo)
CROSBI ID: 713449 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
CURRENT TRENDS IN ACTIVITY AND SELECTIVITY PROFILING OF THERAPEUTIC MOLECULES
Autori
Glavaš-Obrovac, Ljubica
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
International Scientific and Professional Conference 15th Ružička days “TODAY SCIENCE – TOMMOROW INDUSTRY” - Book of abstracts
/ Drago Šubarić - Osijek, 2014
Skup
International Scientific and Professional Conference 15th Ružička days “TODAY SCIENCE – TOMMOROW INDUSTRY”
Mjesto i datum
Vukovar, Hrvatska, 11.09.2014. - 12.09.2014
Vrsta sudjelovanja
Plenarno
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
drug disovery; target-specific assays; phenotypic profiling; affinity; selectivity
Sažetak
Drug discovery is a long process starts with identification and validation of a new “druggable” target followed by testing many natural or synthetic compounds in assays relevant to the disease in question. A considerable portion of drug discovery process focuses on the target-specific assays, as well as those that assess off-target effects and cytotoxicity, which are all helpful in generating a broad profile of tested compounds reactivity. Carrying out numbers of studies prior to clinical trials such as improved toxicity testing in vitro and in vivo, establishing predictive translations models based on a thorough disease understanding and identifying biomarkers my help in the activity profiling of compounds with therapeutic potential. High affinity and selectivity are two of the most required properties of therapeutic molecules. Selectivity has been difficult to achieve, especially for targets that belong to large families of structurally and functionally related proteins. There are two ways by which selectivity can be improved during optimization: a chemical modification of the lead compound that improves the affinity towards the target to a higher extent than to off-target molecules, and a chemical modification that lowers the affinity of the lead compound towards off-target molecules. Maximal selectivity is achieved when both mechanisms can be combined synergistically. After high-throughput screening, hit compound identification, lead compound optimization, the drug discovery process ends with the launch of new active therapeutic molecules.
Izvorni jezik
Engleski
Znanstvena područja
Kemija, Biologija, Temeljne medicinske znanosti